SPI1 and Autoimmunity: Of note, pathogenic myeloid cell activity in the context of autoimmunity and chronic inflammatory disease has been attributed to PU.1-dependent gene programs (Fang et al., 2022), raising the question as to whether PU.1 activity constitutes a potential therapeutic target.